Cargando…
Comments on Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491
In contrast to the prevailing arguments presented in the current review, the incidence of neutralising antibody (NAb) formation is not a significant issue for any of the present type A therapeutic botulinum neurotoxin (BoNT) products. Furthermore, clinical non-responsiveness is poorly correlated wit...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076756/ https://www.ncbi.nlm.nih.gov/pubmed/31979238 http://dx.doi.org/10.3390/toxins12020071 |